Tamarly Intelligence
Company · GILD (Nasdaq)

Gilead Sciences, Inc.

Biological Products, (No Diagnostic Substances)

Key figures
Revenue, 2025
$29.44B
Employees
17,000
Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Institutional holders
2,274 at 30 Jun 2026 (2,325 the quarter before)
SEC number
882095
LEI
549300WTZWR07K8MNV44

Source: SEC EDGAR filings and company facts, SEC Form 13F; checked 27 Oct 2026

About

Gilead Sciences, Inc. is an American biopharmaceutical company in pharmaceutical industry, headquartered in Foster City, founded in 1987.

Source: Wikidata

Latest filings
6 Aug 2026
10-Q FORM 10-Q
4 Aug 2026
8-K FORM 8-K
3 Aug 2026
13F-HR 13F-HR
20 May 2026
8-K FORM 8-K
8 May 2026
13F-HR 13F-HR

Source: SEC EDGAR

With a free account

A free account opens 10 full pages a month and lets you follow this page: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.

Start freeSign in

Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.

Gilead Sciences, Inc.: Revenue $29.44B (2025), filings, holders and country risk | Tamarly